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Recommendations
Table 1
Summary of ICFSR evidence-based recommendations and clinical considerations for the identification and management of 
frailty in older adults 
Recommendation Grade Certainty of Evidence
Frailty Screening
1 All adults aged 65 years and over should be offered screening for frailty using a validated 
rapid frailty instrument suitable to the specific setting or context
Strong Low
Frailty Assessment
2 Clinical assessment of frailty should be performed for all older adults screening as positive for 
frailty or pre-frailty
Strong Low
Development of a Comprehensive Management Plan
3 A comprehensive care plan for frailty should systematically address polypharmacy, the mana-
gement of sarcopenia, treatable causes of weight loss, and the causes of fatigue (depression, 
anaemia, hypotension, hypothyroidism, and vitamin B12 deficiency)
Strong Very Low
4 Where appropriate, persons with advanced (severe) frailty should be referred to a geriatrician CBR No data†
Physical Activity/Exercise
5 Older people with frailty should be offered a multi-component physical activity programme 
(or those with pre-frailty as a preventative component)
Strong Moderate
6 Health practitioners are strongly encouraged to refer older people with frailty to physical 
activity programmes with a progressive, resistance-training component
Strong Moderate
Nutrition and Oral Health
7 Protein/caloric supplementation can be considered for persons with frailty when weight loss 
or undernutrition has been diagnosed
Conditional Very Low
8 Health practitioners may offer nutritional/protein supplementation paired with physical acti-
vity prescription 
Conditional Low
9 Advise older adults with frailty about the importance of oral health  CBR No data†
Pharmacological Intervention
10 Pharmacological treatment as presently available is not recommended therapy for the treat-
ment of frailty
CBR Very Low
Additional Therapies and Treatments
11 Vitamin D supplementation is not recommended for the treatment of frailty unless vitamin D 
deficiency is present
CBR Very low
12 Cognitive or problem-solving therapy is not systematically recommended for the treatment of 
frailty 
CBR Very low
13 Hormone therapy is not recommended for the treatment of frailty CBR Very low
14 All persons with frailty may be offered social support as needed to address unmet needs and 
encourage adherence to the Comprehensive Management Plan
Strong Very low
15 Persons with frailty can be referred to home-based training Conditional Low
Where sufficient evidence was available from systematic reviews/meta-analyses, recommendations were ranked according to the GRADE approach (1). Where evidence was limited in 
systematic reviews/meta-analyses or for topics beyond the scope of systematic reviews, Consensus Based Recommendations (CBR) were formulated by the International Conference of 
Frailty and Sarcopenia Research (ICFSR) task force on frailty; † ‘No data’ indicates no data identified by systematic reviews. 
THE JOURNAL OF NUTRITION, HEALTH & AGING©
J Nutr Health Aging
Volume 23, Number 9, 2019
773
Introduction
Frailty is prevalent in all countries and is a leading 
contributor to functional decline and early mortality in older 
adults (2-4). The condition is defined as “a clinical state in 
which there is an increase in an individual’s vulnerability 
for developing an increased dependency and/or mortality 
when exposed to a stressor” (5). Frailty can begin before 65 
years of age, but the onset escalates in those aged 70 years 
and over (6). Nonetheless, frailty is not an obligatory part 
of the ageing process, and many adults reach advanced ages 
without developing frailty (7). Accordingly, various long-term 
risk factors of frailty, like overweight/obesity (8,9), physical 
inactivity (10), cardiovascular risk (11, 12), self-rated health 
(13), and alcohol use (14) have been identified. 
The current estimate of physical frailty prevalence is around 
15% for adults aged 65 years and over, based on a recent 
meta-analysis of community-dwelling older Europeans (15). In 
adults aged over 85 years, prevalence increases to over 25%. 
(16) Frailty prevalence is also elevated in persons with lower 
education, low socioeconomic position, or from ethnic minority 
groups (17-20).  In addition, women tend to have a higher 
prevalence of frailty than men (6, 16, 20-23), although they 
may be more resistant to decline in frailty status over time (24). 
The number of older adults with frailty is increasing, likely due 
to increased survival of older adults with co-morbidities, more 
exposure to sedentary lifestyles, and smaller social support 
networks (25-27).
There is much potential for frailty to be reversed, particularly 
in its early stages (28-30). For that reason, early identification 
and management of frailty is an important priority for both 
healthcare providers and healthcare policy makers (31-33). 
This paper presents international Clinical Practice Guidelines 
(CPGs) for the identification and management of frailty.
Guideline Objectives
These CPGs (hereafter known as “guidelines”) were 
developed to help ensure that all older people living with frailty 
are provided with high-quality, evidence-based care. The target 
audience for these guidelines includes all health professionals 
who contribute to the care of older people with frailty, including 
clinicians and allied health professionals; the target patient 
population includes all older adults with either frailty or at 
risk of frailty. These guidelines are not targeted towards those 
persons who already have well-established disability. The 
guidelines are applicable to both the hospital and primary care 
setting. 
It is expected that implementation of these CPGs will 
improve both the short- and long-term outcomes of older adults 
with frailty. The guidelines aim to maintain or improve the 
physical function, health and experience of the care process for 
older people with frailty. Continuity of care is encouraged. An 
outline of current, relevant evidence will be provided regarding 
screening, assessment and management of frailty in older 
adults. Health practitioners will use these guidelines differently 
depending on their care setting and expertise. It is anticipated 
that national, state and local policy makers will be able to 
utilise these guidelines to develop health, social and aged care 
policies specific for older adults with frailty. Although these 
are international guidelines for frailty, the evidence-base comes 
predominantly from high-income countries.
What is Physical Frailty?
Physical frailty can be considered as pre-disability, with 
disability defined as needing assistance with basic Activities of 
Daily Living (ADL). Figure 1 outlines the cascade of functional 
decline in older adults from independence through to frailty and 
disability. Targeted intervention can stall, slow or reverse this 
cascade of decline.
 
Figure 1
The cascade of functional decline in older adults from 
independence, through to frailty and disability (in the absence 
of intervention) [Based on concepts and findings by Dapp et 
al.  (34) Hoogendijk et al. (35), Clegg et al. (36) and Fried et al. 
(37)] 
Frailty was first described by Fried and colleagues (37) in 
terms of its physical characteristics, or ‘phenotype’, and is 
objectively identified as three or more of five components: 
weakness (low grip strength), slowness (slow walking speed), 
shrinking (unintentional weight loss), exhaustion (self-
reported), and low physical activity (37). Weight loss is usually 
the last of these five physical characteristics to manifest (38), 
and it is noted that once weight loss has occurred, it is very 
difficult to improve or reverse frailty status and physical 
functioning (39, 40). Understandably, the ‘anorexia of ageing’, 
which is age-related appetite and weight loss, is closely linked 
with the development of physical frailty (41-44). 
Physical frailty is also related to sarcopenia [low muscle 
strength and/or muscle quantity of quality] (45-48), with 
clinical management of the two conditions overlapping 
somewhat (33, 49). Co-morbidity and disability also overlap 
with frailty, although they are both clinically and conceptually 
distinct (50, 51). For instance, among older people with frailty 
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in the Montreal Unmet Needs Study (MUNS), 29.1% of 
people had an ADL disability and 81.8% had one or more 
co-morbidities. That is, although it is common for people with 
frailty to have disability or co-morbidity, a person can be frail 
without any co-morbidity or ADL disability, and vice versa. 
There is also a distinction between frailty and vulnerability, 
with frailty generally considered to be a severe state of 
vulnerability, where small perturbations in internal/external 
stressors can lead to functional decline (51). 
Frailty is a dynamic entity where an individual can transition 
between states. For example, hospitalisation can transition an 
older adult from robust to frail (24, 52). On the other hand, 
being physically active may reverse frailty development - at 
least partially (29, 53, 54). Thus, understanding how an older 
person can dynamically move in and out of frailty states is 
important for both prevention and management of the condition. 
Guideline Development Process
These guidelines were formed by the International 
Conference of Frailty and Sarcopenia Research (ICFSR) which 
is an international alliance of subject-matter experts in the fields 
of both frailty and sarcopenia. An ICFSR expert working group 
on frailty (referred to as the ‘task force’ hereon) was formed, 
and included a multidisciplinary panel of practicing clinicians 
(predominantly geriatricians), Allied Health Professionals 
(AHPs), Primary Care Physicians (PCPs), musculoskeletal 
physiologists, gerontologists, and methodology experts. A 
steering committee was formed from the task force members, 
and was responsible for overseeing the development and 
review of the guideline development process. Input was also 
sought from four external reviewing groups: (i) two healthcare 
provider reviewing groups comprised of PCPs, therapists, 
geriatricians, nurse practitioners, residents in geriatric medicine, 
nurses specialising in geriatric medicine, and AHPs [Perry 
County, USA (n=7) and Madrid, Spain (n=15)]; and (ii) 
two healthcare consumer groups of older people with frailty 
[Perry County, USA (n=12) and Madrid, Spain (n=10)] (See 
Appendix).
Guidelines were developed using the Grading of 
Recommendations, Assessment, Development and Evaluation 
(GRADE) approach, which is an objective, structured system 
of ranking the strength and certainty (quality) of the supporting 
evidence behind each recommendation (guideline) (1). Where 
the evidence-base was limited or of low quality, Consensus 
Based Recommendations (CBRs) were formulated by the task 
force. These CBRs were voted on by task force members via 
an emailed survey, and a draft manuscript formed. The draft 
manuscript and included recommendations were then reviewed 
and discussed at the ICSFR task force workshop as part of 
the annual ICFSR conference (February 2019, Miami USA). 
Further iterations of the recommendations and manuscript were 
then made via email using an iterative Delphi process of expert 
consensus (55). 
The recommendations focus on core practices for the 
identification and management of frailty in older adults and 
consider lifestyle factors as well as the clinical and practical 
aspects of care. We focus on physical frailty to enable us to 
divert from including comorbidity scales and psychosocial 
frailty. The management of multidimensional frailty and 
subtypes of frailty (cognitive, social and nutritional) are beyond 
scope. Although these guidelines do not specifically focus on 
the prevention of frailty, many recommendations are relevant 
to frailty prevention. A user-friendly patient information guide 
was also developed which was based on feedback from older 
adults with frailty and their caregivers (see Appendix).
Searching the Evidence
These guidelines were informed by two systematic reviews 
which used the GRADE approach (56, 57), a systematic 
overview which also used the GRADE process (58), and other 
systematic reviews which included trials defining frailty using 
an objective, validated instrument (56, 58-63). In addition to the 
randomised clinical trials (RCTs) covered in these systematic 
reviews, relevant trials defining frailty objectively using a 
validated instrument were identified through comprehensive 
literature searches using PubMed and Scopus databases. 
Search term combinations included “frailty/diagnosis”, 
“frailty/therapy*”, “patient care planning/standards”, 
“geriatric assessment/statistics and numerical data”, “aged”, 
“intervention” and “treatment”.  The libraries of task force 
members were also used to identify additional clinical trials on 
frailty treatment and management. Interventions focusing on 
community-dwelling older adults were prioritised to promote 
generalisability of the guidelines. Where RCTs were absent, 
other experimental designs such as observational studies were 
considered.
The Population, Intervention, Comparator and Outcomes 
(PICO) question used to inform the literature search query was: 
For older adults with frailty or risk of frailty with or without 
co-morbid conditions and either residing in the community 
or currently admitted to hospital/a rehabilitation setting (P), 
what are the relative benefits and harms of different treatment/
management strategies reported in randomised clinical trials 
(RCTs) (I) compared to usual care or placebo treatment (C) on 
change in physical frailty status or functioning between baseline 
and follow-up measured using a validated frailty instrument or 
a physical performance measure (O). Secondary outcomes were 
quality of life (QoL), cost effectiveness, physical performance 
measurement and any adverse clinical outcome. These primary 
and secondary outcomes were informed by a recent protocol 
paper (64).
Grading the Strength and Certainty of Evidence: GRADE 
approach
The strength and certainty (quality) of evidence was 
evaluated for each recommendation as per the GRADE 
approach (1) where possible (See Table 2); specifically, 
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this approach involves a formal assessment of the strength 
and certainty of evidence by outcome. The strength of a 
recommendation reflected the harm-benefit balance, patient 
values and preferences, cost-effectiveness and the quality 
of supporting evidence (65, 66). A strong recommendation 
indicated that the intervention was likely to have benefits that 
outweighed any risk, and that most clinicians would prescribe 
this intervention (65, 66). A conditional recommendation 
implied that whilst many clinicians would prescribe the 
intervention, many would not because of the fine balance 
between harms and benefits of the intervention (1, 67) (see 
Table 2). In addition, when grading the strength of each 
recommendation, the ICFSR task force strongly focused on 
two aspects from the GRADE Evidence-to-Decision (EtD) 
framework (1, 67): (i) person-centred outcomes important to 
older adults; and (ii) the number of older adults with frailty 
who would likely benefit from the intervention. Barriers to 
implementation of the guidelines (such as resources and access 
to services) were also considered by the task force when 
assigning grades to each recommendation. 
The certainty of evidence signified the overall certainty 
regarding the effectiveness of the intervention, and 
incorporated information regarding the trial design and number 
of participants, risk of bias, imprecision, inconsistency, 
indirectness and publication bias (1, 67). There were four 
gradings of certainty of evidence: high, moderate, low and very 
low (Table 2). 
Frailty Screening
Recommendation 1: All adults aged 65 years and over 
should be offered opportunistic screening for frailty using 
a simple, validated frailty instrument suitable to the specific 
setting or context (Strong recommendation; low certainty of 
evidence)
The task force strongly recommends that older adults 
should be screened for frailty using a simple, validated 
frailty instrument suitable to the specific setting or context 
(task force agreement with recommendation: 78.9%). This 
recommendation also received unanimous support by the 
external reviewing group of healthcare providers, and strong 
support by both patient consumer groups. 
Background: the rationale for frailty screening
The global burden of frailty has spurred an international 
effort to identify which instrument is most suited for frailty 
screening. An ideal screening tool needs to be effective not only 
in resource-limited areas, but also in developed countries where 
access to geriatric screening is often lacking. Frailty screening 
usually involves the recognition of functional decline alongside 
various other components which may or may not include slow 
gait speed, weight loss, cognitive difficulties, and exhaustion, 
depending on which screening tool is used. 
Primary care appears to be the logical place to screen or case 
identify frailty in older persons (68, 69), particularly in its early 
stages when it is more likely to be amenable to intervention 
Table 2
Categorical definitions for the strength and certainty of evidence, as per GRADE guidelines (1)
Category Description
Strength of the Recommendation 
Strong A strong recommendation indicates that the benefits of the intervention likely outweigh any associated 
risk; most clinicians would prescribe this intervention, and most patients would want to receive this 
type of intervention (65, 66).
Conditional (Weak) A conditional recommendation indicates that clinicians would only refer the intervention under specific 
conditions because there is a fine balance between risks and burdens. Whilst many health practitioners 
would recommend the intervention, others would not; burdens include unwanted side effects and 
increased risk of adverse outcomes which undermine the health benefits of the intervention (57, 58). 
A conditional recommendation was also given when patient values were unknown regarding the 
intervention, or if there was substantial variation in patient preferences/values (1, 67)
Certainty of Evidence† 
High Further research is very unlikely to change confidence in the estimate of effect.
Moderate Further research is likely to have an important impact on our confidence in the estimate of effect and 
may change the estimate. 
Low Further research is very likely to have an important impact on our confidence in the estimate of effect 
and is likely to change the estimate.
Very Low Any estimate of effect is very uncertain.
† As per the GRADE approach, the certainty of evidence was ranked lower by the task force when the following existed: study design limitation (including inconsistencies) and/or 
uncertainties (such as sparse or imprecise data, or indirect evidence); certainty of evidence was ranked higher when there was evidence of a dose-response gradient, no major threats to 
the validity of supporting studies, and/or consistent evidence with no confounding variables. 
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(28, 29, 31). However, many primary care practices (PCPs) 
are facing excessive patient loads, and must also divide their 
attention between diagnosing and managing chronic and 
infectious diseases that their older patients may present with. 
Further to this, many older adults have difficulties accessing 
health care services (70), which in turn is a major barrier to 
timely identification of frailty. Thus frailty should be identified 
in all healthcare encounters (33, 71). 
Which screening instrument to use?
A frailty screening instrument needs to be efficient 
in identifying frailty (72). Currently, there exists a large 
assortment of frailty screening instruments, each with a variety 
of included components. Screening tools recommended by the 
ICFSR task force include Rockwood’s Clinical Frailty Scale 
(CFS) (73), the International Association of Nutrition and 
Ageing (IANA)’s FRAIL scale (74), and the Edmonton Frailty 
Scale (EFS) (75). The CFS is based on clinical judgement, and 
involves a nine-point pictorial scale paired with corresponding 
text describing classifications of frailty (73). At scores higher 
than 6, an individual can be considered as having a disability 
in ADL rather than frailty per se. Recently, the International 
Consortium for Health Outcomes Measurement (ICHOM) has 
recommended the CFS as part of its standard set of outcome 
measurements for studies of older adults (76). The FRAIL scale 
comprises five components: Fatigue, Resistance, Ambulation 
(slow walking speed), Illness and Loss of Weight (5% or more 
in the previous year) and can be derived from pre-collected 
patient data (74, 77). It has been validated to predict poor 
outcomes such as disability and mortality, when disability is 
excluded from the original cohort (74). A treatment algorithm 
has been developed utilising its five components (78). FRAIL 
has been recommended in Australia as a screen for all older 
persons, where it can act as a “canary in the coal mine” (79); 
the Australian Government’s MyAgedCare website (the main 
point of entry into the aged care system), details information for 
older adults and aged care providers on how to use the FRAIL 
scale. The FRAIL scale is also predictive of physical limitation 
and mortality to a similar extent as the frailty phenotype of 
Fried and colleagues (80). The EFS includes nine components: 
functional limitation, self-reported health, general health status, 
cognition, social support, mood, functional performance, 
polypharmacy and continence (75), and is most commonly used 
in the hospital setting (81). It is also suitable for the community 
setting (82).
The evidence-base for frailty screening
Many frailty screening instruments are well established as 
predictors of adverse outcomes such as mortality, functional 
decline and long hospital stays (3, 73, 83-87). However, 
only low-certainty evidence has found that frailty screening 
is effective at informing treatment decisions and recovery 
expectations in a specialist setting (88). Indeed, the evidence-
base showing that frailty screening leads to improved 
management of older people with frailty is lacking. This may 
be explained in instruments such as CFS by its focus on clinical 
diagnoses of disease and disability and, therefore, there is 
limited overlap with clinical frailty. In settings such as acute 
unplanned care, screening may actually have no influence 
on clinical decision-making regarding patient care and 
management (63, 89, 90). 
Overall, there is a lack of current evidence to support 
systematic screening of frailty for all older adults, at least 
according to a 2018 comprehensive review (91). Many frailty 
screening instruments are also not validated for use in low-
middle income countries (LMICs) based on a systematic review 
by Gray and colleagues (2016) (72). 
Who should conduct frailty screening?
A range of health practitioners may perform frailty 
screening, including geriatricians, PCPs, nurses, medical 
specialists and allied health professionals. It is important 
that health practitioners receive appropriate training on 
frailty screening. Importantly, some members of the patient 
consumer group suggested that older adults could also become 
empowered to identify frailty in themselves.
Barriers to frailty screening  
There are number of significant barriers to the 
implementation of frailty screening programmes, including a 
lack of public awareness of frailty, difficulties for older persons 
to access and afford primary care services, the acceptability of 
screening to older adults, and a lack of clarity regarding which 
treatment pathways should follow screening/diagnosis (70,91). 
Primary care practices also face difficulties when adding an 
additional component to patient consultation visits. 
Is frailty screening cost effective?
Due to the very low certainty of evidence on the cost-
effectiveness of frailty screening (92), it is unclear whether 
the benefits of frailty screening outweigh its cost. Evidence 
to support the cost-effectiveness of frailty screening comes 
predominantly from a recent clinical trial by Bleijenberg and 
colleagues (93) which reported that proactive screening for 
frailty in primary care was associated with a high probability 
of cost-effectiveness (85). However, a recent meta-analysis of 
the Dutch proactive approaches (which also included data from 
the study by Bleijenberg and colleagues) highlighted that frailty 
screening is not likely to be cost-effective (86). 
Physical Frailty Assessment
Recommendation 2: Clinical assessment of frailty should 
be performed for all older adults screening as positive for 
frailty or pre-frailty (Strong recommendation; low certainty of 
evidence) 
The task force strongly agreed that the clinical assessment 
of frailty should be performed for all older adults screened 
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as positive for frailty or pre-frailty (task force agreement 
with recommendation: 94.7%). This recommendation was 
universally supported by the healthcare provider reviewing 
groups and the two patient consumer groups. 
Assessment of physical frailty
Frailty can be clinically assessed using various criteria. The 
ICFSR recommended standard for clinical frailty assessment is 
the highly validated physical frailty phenotype, developed by 
Fried and colleagues in 2001 (37). An older person is classified 
as frail when three or more of these five components are 
present; pre-frailty is classified when one or two components 
exist (37). Moderate-certainty evidence has demonstrated that 
frailty assessment using Fried’s frailty phenotype is beneficial 
for older people with frailty. 
It is important clinically to differentiate frailty from 
multi-morbidity and disability because management of these 
conditions differs. A Comprehensive Geriatric Assessment 
(CGA) (68) is too complex to be used as a frailty assessment 
tool and can miss frailty as it was originally designed to assess 
disability (and contributing medical conditions) in older adults 
before the concept of frailty existed clinically (95). Thus, 
CGA tends to be more disability- rather than frailty-centric. In 
addition, the quality of a CGA assessment depends on the time 
and quality spent on its application, and understandably there 
is likely to be much variation in quality and content. Further 
to this, CGA assessment can be costly to perform and may 
not be feasible in low resource settings (33). Notwithstanding 
this, a comprehensive management plan for older adults can be 
informed by a CGA (96), and an adapted CGA (68, 97) may be 
performed to identify any underlying causes of frailty.  
Who should conduct frailty assessment?
Frailty assessment should be performed by a health 
practitioner who has had specific training in frailty assessment. 
This assessment is not limited to geriatricians, but also includes 
other medical specialists, PCPs, and allied health professionals 
who have undertaken geriatric training. 
Development of a Comprehensive Management Plan
Recommendation 3: A comprehensive care plan for 
frailty should systematically address: polypharmacy, the 
management of sarcopenia, treatable causes of weight 
loss, and the causes of exhaustion (depression, anaemia, 
hypotension, hypothyroidism, and vitamin B12 deficiency) 
(Strong recommendation; very low certainty of evidence)
There was strong agreement by the ICFSR task force that 
a treatment/comprehensive care plan be implemented for all 
older adults with frailty, keeping in line with an older person’s 
preferences, goals and level of frailty (task force agreement 
with recommendation: 89.5%). This care plan should include 
the treatment of sarcopenia, polypharmacy, exhaustion causes 
(depression, anaemia, hypotension, hypothyroidism, and B12 
deficiency), and treatable causes of weight loss/undernutrition 
(5, 33, 98). Fatigue is also the result of various co-morbidities 
such as cardiac failure, and the task force suggest that a clinical 
evaluation be performed to exclude other causes of fatigue. The 
external healthcare provider reviewing groups also strongly 
agreed with this recommendation.    
The evidence-base for the development of a comprehensive 
care plan 
Genuine evidence on the effectiveness of a comprehensive 
management plan for frailty is emerging. An evaluation of 
the evidence-base found that a very low certainty of evidence 
existed regarding the effectiveness of individually tailored care 
plans for older adults with frailty. This evaluation was based on 
a recent systematic review (57), which covered three relevant 
clinical trials (99-101). Importantly, an individualised care and 
support plan to manage frailty in older adults is endorsed in a 
recent report by the British Geriatrics Society (BGS), Age UK 
and the Royal College of General Practitioners (RCGP) (68).
Treatment of Sarcopenia
Given the close link between reduced muscle strength and 
frailty, it is recommended that strategies for the management 
of sarcopenia are also adopted for older adults with frailty. 
The recent ICFSR guidelines for sarcopenia discuss specific 
strategies to improve aspects of sarcopenia (muscle strength, 
function, and muscle mass) (49). An additional benefit of 
focusing on the treatment of sarcopenia is that an International 
Classification of Diseases, Tenth Revision, Clinical 
Modification (ICD-10-CM) code has been recently awarded 
to sarcopenia (102, 103), which may be beneficial in terms 
of claiming for healthcare reimbursement, depending on the 
country.
Exhaustion causes 
Older adults with either frailty or pre-frailty should be 
assessed for fatigue causes. A recent large-scale study from 
both Dutch and Italian datasets (the Longitudinal Ageing 
Study of Amsterdam (LASA) and Invecchiare in Chianti 
(InCHIANTI) respectively) reported that exhaustion (fatigue) 
was the first frailty symptom to manifest in older adults (38). 
Major causal factors for exhaustion include: depression (102, 
104); sleep apnea (105, 106); vitamin B12 deficiency (102); 
hypothyroidism (104, 105); anemia (107, 108); and hypotension 
(109).
Avoidance of medication-related harm by reducing 
polypharmacy 
A 2019 meta-analysis of 37 studies by Palmer and 
colleagues reported that 59% of older people with frailty are 
medicated with five or more medications (polypharmacy) 
(110). Medication management is recommended as part of a 
comprehensive management plan for frailty by the ICFSR task 
PHYSICAL FRAILTY
J Nutr Health Aging
Volume 23, Number 9, 2019
778
force. Appropriate de-prescription (medication withdrawal) to 
target polypharmacy is also recommended. A major point of 
contention with regards to de-prescribing in older people with 
frailty is the disagreement between pharmacists and clinicians 
regarding which medications to de-prescribe and how many 
should be de-prescribed (111). It is therefore recommended by 
the ICFSR task force that de-prescribing for older adults with 
frailty should occur using standard guidelines such as from 
the Screening Tool of Older Person’s Prescriptions (STOPP) 
criteria (112-114) or Beers Criteria (116). The recent Asia 
Pacific clinical practice guidelines for frailty (33) and the best 
practice guideline report for the management of frailty (68) 
also support de-prescribing. Recently developed, although 
not yet externally validated, is a frailty-specific STOPP 
recommendation for use by clinicians (termed STOPPFrail), 
which outlines 27 criteria which of potentially inappropriate 
medications for older adults with frailty (114). 
The task force recommendation to de-prescribe is based on 
a limited evidence base. The majority of systematic reviews 
of frailty interventions in community dwelling older adults 
have not focused on the effectiveness of de-prescription (56, 
57). There is also a lack of evidence regarding the safety and 
effectiveness of medications in older adults with frailty (117). 
Two systematic reviews specifically on older people with 
frailty have reported that:
• The number of studies investigating the reduction of 
polypharmacy is low, and the risk-to-harm ratio is not clear 
(118).
• A systematic mapping review of frailty interventions in 
hospital emergency departments (EDs) by Preston et al.  (63) 
reported that there was some evidence, albeit of very low 
certainty, that reviewing medications using implicit criteria 
reduced ED readmissions; 
Targeting polypharmacy for older people with frailty has 
been found to have no significant impact on mortality or other 
adverse outcomes, at least based on results from a recent RCT 
on de-prescribing in older Australians living in residential aged 
care facilities (RACFs) (n = 47 intervention; n = 48 control) 
(119). In this study, all RACF residents over 65 years were 
considered as frail. 
Other strategies
All older persons with frailty should be assessed for visual 
and hearing difficulties and these should be corrected when 
present. Those who are at risk of falling should be checked for 
orthostatic hypotension and syncope (120).
Recommendation 4: Where appropriate, persons with 
advanced (severe) frailty should be referred to a geriatrician 
(CBR; no data)
The task force unanimously agreed that where appropriate, 
older persons with severe frailty should be referred to 
a geriatrician (task force agreement with recommendation: 
100%). This recommendation reflects the expertise of 
geriatricians in managing more complex cases of frailty (121). 
There was support for this recommendation by the healthcare 
provider reviewing groups, although it was highlighted that in 
a rural area, geriatricians were not locally available and there 
were long drives/wait lists for initial consultations. In such 
cases, PCP management of frailty is required. 
Physical Activity 
Recommendation 5: Older people with frailty should be 
offered a multi-component physical activity programme (or 
those with pre-frailty as a preventative component) (Strong 
recommendation; moderate certainty of evidence)
There was a strong agreement from the task force that 
multicomponent physical activity should be recommended 
for all older adults with frailty (or pre-frailty as a preventative 
component) (task force agreement with recommendation: 
94.7%). The healthcare provider reviewing groups completely 
agreed with this recommendation, suggesting that all physical 
activity programmes be made available by a referral process. 
Similarly, there was unanimous agreement amongst the patient 
consumer groups that physical activity was the most feasible 
way to prevent and treat frailty. 
The evidence base for a multi-component physical activity 
programme to manage frailty 
Using GRADE methodology, very low certainty evidence 
revealed the multicomponent physical activity programmes 
(combining resistance-based training with aerobic and balance 
training) were effective at managing frailty in older adults. 
Recent systematic reviews which only include trials of frailty 
treatment (and not combined with frailty prevention trials) 
have reported that multicomponent training improved the 
outcomes of: muscle strength, balance, disability and falls in 
older adults with frailty (59-61). To date, there is insufficient 
evidence that frailty or functional decline can be improved with 
multicomponent programs (59-61), predominantly because very 
few trials actually measure these two variables at both baseline 
and follow-up. 
There was insufficient evidence to identify the optimal 
frequency, intensity, time and type (FITT) of physical 
activity required to treat/manage frailty. Similarly, there was 
insufficient literature to determine the exact combination of 
training modes (aerobic, resistance and balance training) most 
effective for frailty management. Notwithstanding this, it is 
understood that for physical activity programs to be effective 
for those with frailty, a minimal level of intensity and an 
adequate program timespan are needed (122). Group physical 
activity sessions were more likely to be successful in improving 
frailty than individual sessions according to a recent systematic 
review (57), although this premise is based on only two trials 
which did not use qualified trainers. 
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Systematic reviews of physical activity for the treatment of 
frailty have specifically reported that:
• Among older adults with pre-frailty, those who participated 
in group physical activity programs improved in physical 
functioning (SMD = 0.37, 95% CI 0.07 to 0.68; 3 studies) 
(56);
• Physical activity training improved Timed Up and Go 
(TUG) speed in older adults with frailty in four out of five 
trials, walking speed in two out of five trials, and balance 
in one out of three trials (59). The authors concluded that 
multicomponent programs incorporating resistance training 
were most likely to improve functional capacity in those with 
frailty, although they were unable to establish the optimal 
program type;
• The effect of physical activity in older adults with frailty was 
significant in improving normal gait speed (SMD = 0.07m/s, 
95% CI 0.02 to 0.14) and the Short Physical Performance 
Battery (SPPB) (SMD = 2.18, 95% CI 1.56 to 2.80); there 
was no significant effect of physical activity on endurance, 
balance or ADL functional mobility  (60). Due to a scant 
evidence base, the authors were unable to identify which 
training mode was most effective at improving physical 
functioning for those with frailty. A limitation of this review 
was that frailty was not defined using an objective screening/
diagnosis instrument. Rather, frailty was identified according 
to ADL limitation/lowered physical functioning; 
• Among older adults with frailty, physical activity 
intervention led to improvements in gait ability in six out 
of eleven trials, balance in seven out of ten trials, muscle 
strength in nine out of thirteen studies, and a reduction in 
the incidence of falls in seven out of ten trials  (61). The 
authors concluded that a multicomponent physical activity 
intervention program incorporating resistance, endurance 
and balance training was likely to be the best strategy to 
improve physical outcomes in older adults with frailty. A 
limitation of this review was that authors included all studies 
which defined their participants as “physically frail”, which 
included frailty defined by the physical domains of Fried’s 
frailty phenotype, and persons aged 70 years and over with 
functional decline/physical performance impairments. That 
is, included studies did not define solely define frailty using 
an objective frailty instrument. 
• In community-dwelling older adults with physical frailty 
(defined by the frailty phenotype criteria of Fried and 
colleagues), there was very low certainty evidence that 
physical activity improved muscle strength and physical 
performance compared with placebo (systematic overview of 
the literature by Lozano-Montoya et al. with evaluation using 
GRADE criteria) (58). Only one relevant RCT was identified 
in this review (123).
There are additional systematic reviews covering the effects 
of physical activity for older persons with frailty, although 
these are limited by their merging of frailty prevention studies 
(no persons with frailty or pre-frailty at baseline) with frailty 
intervention trials (57), or by including studies defining 
frailty using outdated definitions such as “having multiple 
morbidities”, “resident of an aged care facility”, “dependent in 
ADL” or simply “aged 65 years and over” (124, 125).
Patient consumer feedback regarding physical activity to 
manage frailty
Members of the patient consumer group advised that they 
would need guidance and support to undertake a physical 
activity program, with many preferring group-based classes. 
The majority of patient consumer group members also agreed 
that it would be very difficult to accomplish a physical activity 
program on their own. The importance of increasing physical 
activity and reducing sedentariness was also highlighted by 
members of the patient consumer group. 
Recommendation 6: Health practitioners are strongly 
encouraged to refer older people with frailty to physical 
activity programs with a progressive, resistance-training 
component (Strong recommendation; moderate certainty of 
evidence) 
First-line therapy for the management of frailty should 
include a multi-component physical activity program with a 
resistance-based training component (task force agreement with 
recommendation: 94.7%). There were two main reasons as to 
this strong recommendation by the task force: (i) the strong 
dose-response relationship found in clinical trials of resistance 
training in older adults with frailty; and (ii) the agreement by 
both patient consumer groups as to the importance of resistance 
training. 
The evidence base for resistance-based training
Moderate-certainty of evidence showed that older adults with 
frailty improve in their frailty status and physical performance 
when undergoing either progressive resistance-based training 
or a multicomponent physical activity program containing 
resistance-based training (57). Resistance-based training 
includes any physical activity which uses external resistance 
(such as from dumbbells, machine-based weight training, 
hydraulic resistance (water-based resistance training) elastic 
therapy bands, and body weight) to produce skeletal muscle 
contractions at levels higher than during routine activity (49). 
Nutrition and Oral Health
Recommendation 7: Protein/caloric supplementation 
can be considered for persons with frailty when weight 
loss or undernutrition has been diagnosed (Conditional 
recommendation; very low certainty of evidence). 
Recent systematic reviews indicate that in observational 
studies, undernutrition in community-dwelling older adults 
is closely associated with frailty (126, 127). However, when 
intervention trials are considered, only very low certainty 
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evidence supports protein/caloric supplementation for older 
adults with frailty (58). Indeed, the benefits of protein/caloric 
supplementation are debatable if no weight loss, undernutrition 
or sarcopenia are present. The task force therefore recommend 
protein and/or caloric supplementation in older adults with 
frailty when weight loss is present or undernutrition has been 
diagnosed (task force agreement with recommendation: 78.9%). 
Both healthcare provider reviewing groups generally agreed 
with this statement, as did the majority of consumer group 
participants (see Appendix 1.2). 
Also suggested by the task force was that a formal diagnosis 
of undernutrition be obtained as a basis to the recommendation 
of nutritional supplementation (128). 
The evidence-base for protein/caloric supplementation
The evidence-base on nutritional supplementation is 
heterogeneous in terms of study outcomes and firm conclusions 
cannot be inferred. Systematic reviews of protein and/or caloric 
supplementation have reported the following:
• In community-dwelling older adults with physical 
frailty (defined by the frailty phenotype criteria of Fried 
and colleagues), it was uncertain whether phospholipid 
supplementation improved muscle strength or physical 
performance compared with placebo; evaluation with 
GRADE criteria showed a very low certainty of evidence 
for all outcomes, with a very serious risk of bias and serious 
issues with both imprecision  and indirectness (applicability/
generalisability) (58); 
• Among older adults with frailty, protein-energy/
protein supplementation led to increases in physical 
performance and strength (gait/leg strength) with a moderate-
certainty of evidence (evaluated using GRADE criteria), as well 
as improvements in gait speed and frailty with a low-certainty 
of evidence  (57). However, this result was deduced from only 
three small-scale (n < 200) clinical trials with frailty/physical 
performance as outcomes measures (123, 129, 130). These 
trials had selection biases (allocation concealment issues and 
lack of randomisation), performance biases (participants/study 
personnel not properly blinded to the study protocol), and 
attrition bias resulting in incomplete outcome data (57);
• When studies of older adults with pre-frailty were examined 
in the meta-analysis by Frost and colleagues  (56), no studies 
of protein/caloric supplementation were identified.  
Dietary Food Quality
Overall dietary quality may influence the progression of 
frailty in older adults (53, 54, 131). For instance, low-level 
evidence from prospective cohort studies has demonstrated 
that a traditional Mediterranean diet can reduce frailty risk in 
community-dwelling older persons (132-134). These findings 
were supported by a 2018 meta-analysis which reported that 
good adherence to a Mediterranean diet significantly reduced 
incident frailty [OR (95% CI) = 0-.47-0.82] (135). Lack of 
dietary nutrient quality may also accelerate the progression 
of frailty, with a recent systematic review reporting that 
micronutrients such as folate, β-carotene, and vitamins A, C 
and E associate with the development of frailty (136). 
However, studies of dietary quality (including micronutrient 
intake) have focused primarily on the prevention of frailty 
development. What is not known is the effect of dietary quality 
for the treatment/management of already established frailty. 
Clinical trials involving older adults with frailty are therefore 
needed to form an evidence-base regarding the benefits of 
dietary quality for the management of frailty in older adults. 
 
Treatable causes of weight loss in older adults
Treatable causes of weight loss can be identified by the 
MEALS-ON-WHEELS mnemonic (137, 138): 
Medications
Emotional (depression)
Alcoholism, anorexia tardive, abuse (elder)
Late life paranoia
Swallowing problems
Oral problems
Nosocomial infections, no money (poverty)
Wandering/dementia
Hyperthyroidism, hypercalcemia, hypoadrenalism
Enteric problems (malabsorption)
Eating problems (eg, tremor)
Low salt, low cholesterol diet
Shopping and meal preparation problems, stones (cholecystitis)
Patient consumer group feedback regarding nutritional 
supplementation to manage/treat frailty 
No members of the Spanish patient consumer group 
considered that supplements would be needed to treat frailty, 
with participants preferring to complement physical activity 
with a good, healthy diet, especially a Mediterranean diet. For 
the USA patient consumer group, the majority of members 
suggested that they would not use nutritional supplementation 
to manage frailty, although a few members were unsure and 
suggested that supplements could perhaps only be prescribed if 
diets were deficient. 
Recommendation 8: Health practitioners may offer 
nutritional/protein supplementation paired with physical 
activity prescription (Conditional recommendation; low 
certainty of evidence)
Older people with frailty can be offered nutritional/protein 
supplementation paired with a physical activity program 
(task force agreement with recommendation: 89.5%). Low 
certainty evidence revealed that physical activity combined 
with nutritional intervention is effective at improving frailty, 
gait speed, grip strength and physical performance in older 
adults with frailty and/or pre-frailty (56, 57, 129, 139). The 
majority of this evidence is based on one small-scale RCT 
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(n = 131) of older Japanese women with frailty (123) which 
found that supplementation with milk fat globule membrane 
(MFGM) combined with a 60 min physical activity class (twice 
per week for three months) reduced exhaustion and improved 
walking speed, although did not improve skeletal muscle mass 
or strength. Whilst there are other trials purported to improve 
outcomes for frailty by combining physical activity/nutritional 
supplementation (57), these studies are of older adults receiving 
care services (140), which are more of a population with 
disability, and not necessarily frail.
It is believed that nutritional intervention has an additive 
effect to the benefits of physical activity training, and vice versa 
(54, 56). Notwithstanding this, current clinical trials combining 
physical activity and nutritional supplementation tend to have 
high biases (56).
Recommendation 9: Advise older adults with frailty about 
the importance of oral health (CBR; no data)
The task force suggests that older adults with frailty be 
advised about the importance of oral health. This advice may be 
incorporated as part of routine medical appointments, and can 
include information on oral and denture hygiene (141). Referral 
to oral health specialists is also advisable in some instances 
(141). 
The evidence-base for oral health
Systematic review evidence indicates that oral health is 
associated with frailty, although the majority of research on 
the topic is from cross-sectional studies (142, 143). Older 
adults with frailty are more likely to have edentulism (reduced 
tooth number) and lower occlusal force (bite strength) (144). 
Recent longitudinal studies from Japan have reported that 
older adults with lower occlusal force/reduced chewing 
ability are significantly more likely to develop frailty (145, 
146). Similarly, a study of British community-dwelling older 
people found that incident frailty was higher in older adults 
with edentulism, oral health problems or symptoms of dry 
mouth (147). However, there exists a shortage of clinical trials 
investigating the impact that improved oral health has for older 
persons with frailty.
Pharmacological Intervention
Recommendation 10: Pharmacological treatment as 
presently available is not recommended therapy for the 
treatment of frailty (CBR; very low certainty of evidence)
The task force does not recommend presently available 
pharmacological treatment for the management of frailty (task 
force agreement with recommendation: 89.5%). This statement 
was also supported by both healthcare provider reviewing 
groups. 
The evidence-base behind pharmacological intervention for 
frailty 
Insufficient evidence exists regarding the effectiveness of 
pharmacological interventions for older adults with frailty. It 
is therefore not possible to evaluate whether the benefits of 
pharmacological intervention outweighs the risk of adverse 
outcomes such as unwanted side effects and patient burden. 
Notwithstanding this, several recent studies are paving the 
way forwards with regards to advancing drug development 
for the treatment of frailty (148). It has been proposed that 
pharmacological-based strategies may, in time, be beneficial 
to those older adults with frailty, particularly for those with 
co-morbid conditions which exacerbate frailty (148). However, 
at this point in time, both the European Medicines Agency 
(EMA) and the Food and Drug Administration (FDA) do not 
consider frailty to be an acceptable condition for a medication 
to be approved. 
There exists many challenges for pharmacological trials 
for the management of frailty, including the lack of a standard 
measurement for frailty, and defining exactly who will be in 
clinical trials given the different conceptual understandings 
of frailty (148, 149). Perhaps most notable is that older adults 
with frailty may have co-morbid conditions, and clinicians are 
advised to use their own expert clinical judgement regarding the 
management of these conditions – noting that these conditions 
may indeed warrant specific pharmacological treatment/
management regimes. 
Additional Therapies and Treatments
Recommendation 11: Vitamin D supplementation is not 
systematically recommended for the treatment of frailty unless 
vitamin D deficiency is present (CBR; very low certainty of 
evidence)
The task force does not recommend Vitamin D 
supplementation for the treatment of frailty unless there is 
a clear deficit (task force agreement with recommendation: 
89.5%). This decision is based on disagreement over whether/
how vitamin D supplementation should be prescribed 
for older adults with frailty (57, 150, 151). The healthcare 
provider reviewing groups also did not agree with Vitamin D 
supplementation. 
The evidence-base for Vitamin D supplementation for older 
people with frailty
Frailty is associated with low levels of vitamin D in the 
majority of epidemiological studies (152). Recent meta-analysis 
evidence also suggests that 25-hydroxyvitamin D (25OHD) 
serum levels associate with frailty in a dose-response manner 
(153). However, insufficient evidence exists regarding the 
effectiveness of vitamin D supplementation for older adults 
with frailty. Indeed, there exists a distinct shortage of clinical 
trials which focus exclusively on frailty. Most vitamin D 
trials have targeted the generic population of older adults, 
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with several systematic reviews on the topic reporting mixed 
results (154-158). Furthermore, there is moderate certainty 
evidence that vitamin D supplementation decreases fall rate 
but likely does not influence falls risk, at least according to 
a recent Cochrane review of older adults in hospital or aged 
care facilities (159). Notably, dosing of vitamin D may be 
relevant for fall prevention among frail older adults. Several 
double-blind RCTs comparing vitamin D with or without 
calcium against placebo among frail older adults reduced 
the risk of falling with daily applications of 700 to 1000 IU 
vitamin D (160).  However, several trials testing large bolus 
applications (monthly 60’000 IU (161) to 100’000 IU (162) of 
vitamin D or annual dosing of 300’000 IU (163) to 500’000 
IU (164)) increased fall risk among frail older adults.  In terms 
of improvements in functional outcomes, the evidence-base is 
inconsistent (155-157). Further research is needed on the role of 
vitamin D supplementation in frailty prevention and treatment 
among older adults. 
Recommendation 12: Cognitive or problem-solving therapy 
is not systematically recommended for the treatment of frailty 
(CBR; very low certainty of evidence) 
The task force does not recommend cognitive or problem-
solving therapy for the treatment of frailty (task force 
agreement with recommendation: 78.9%). Current evidence is 
insufficient to adequately evaluate the effectiveness of either 
of these therapies. Although the systematic review of Apostolo 
and colleagues  (57) concludes that moderate-certainty of 
evidence shows cognitive therapy improves frailty, gait speed, 
knee strength and exhaustion levels, this conclusion was based 
on only one clinical trial which had 50 participants in the 
cognitive training intervention (129). Regarding problem 
solving therapy, only one clinical trial was identified by 
Apostolo and colleagues’ review (57), and although this trial 
improved leg extension power and some secondary outcomes 
among older adults with pre-frailty or frailty (combined 
analysis) (n=57 for the problem solving therapy arm of the 
study) (165), the effect was much less than combined physical 
activity/nutritional intervention. 
Recommendat ion 13:  Hormone therapy is  not 
recommended for the treatment of frailty (CBR; very low level 
of certainty)
Given the high degree of uncertainty regarding the 
effectiveness of hormone therapy (33, 57), the ICFSR does 
not recommend hormone therapy for the treatment of frailty 
(task force agreement with recommendation: 89.5%).  A 
systematic review of hormone therapy (57) found only one 
small-scale RCT on the topic (166), with this trial reporting 
that dehydroepiandrosterone and/or atamestane therapy did not 
improve measurements of frailty in older men with low strength 
at baseline. 
Importantly, whilst the task force does not recommend 
hormone therapy for the treatment of frailty, it recognises that 
older people with frailty may require hormone therapy for other 
medical conditions. 
Recommendation 14: All persons with frailty should be 
offered social support as needed to address unmet care needs 
and encourage adherence to the Comprehensive Management 
Plan (Strong recommendation; very low certainty of evidence)
The task force strongly recommends that older people with 
frailty should be offered social support as needed to address 
unmet care needs and encourage adherence to a Comprehensive 
Management Plan. This recommendation is based on consensus 
of best practice (task force agreement with recommendation: 
94.7%). Both patient consumer groups agreed with this 
statement and flagged that those with cognitive deficits would 
especially need this support. 
The evidence-base for social support provision
Social isolation is a major risk factor for the progression 
of frailty in older adults (167, 168). Older adults with frailty 
may need assistance in navigating their health care, and in 
performing instrumental ADLs (IADLs) such as medication 
management and grocery shopping. These difficulties are faced 
by all older adults (70), although are exacerbated with frailty 
(2). It is also important for healthcare providers to consider 
autonomy in processes of care and accessibility of healthcare 
services for older adults with frailty (169).
The impact on social support on outcomes in older persons 
with frailty is uncertain. An exploratory systematic review by 
Gardner et al. (62) reported that in older people with frailty/
risk of frailty, the provision of practical social support showed 
evidence of potential effectiveness in enabling health-behaviour 
change compared with usual care (62). However, there was no 
evidence of effectiveness regarding other outcomes (health/
social care use, mental health, general health, and health 
behaviour).
Recommendation 15: Persons with frailty can be referred 
to home-based training (Conditional; very low certainty of 
evidence)
Home-based training may be considered for older people 
with frailty (task force agreement with recommendation: 
94.7%). Recent systematic review evidence has reported the 
following:
• Providing community-dwelling older persons with frailty 
advice on health behavior improvement has been found 
to improve physical functioning (with a low certainty of 
evidence) based on a systematic review which included six 
trials of health-behaviour improvement (62). No data existed 
regarding health behaviour improvement from the provision 
of health behaviour advice;
• Modifying the home environment to facilitate health 
behavior change was found to improve both the physical 
functioning and health behaviour of older people with frailty 
(very low certainty of evidence) compared with based on a 
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systematic review of five relevant trials (62);
These findings are supported by two recent small-scale 
feasibility trials:
• In community-dwelling persons aged 65 years and over 
with frailty/pre-frailty, a home-based training program 
delivered by trained volunteers (delivering skills in either 
physical activity/nutrition or social support twice weekly) 
improved nutritional and frailty status after 12 weeks (n = 
80) compared with baseline nutrition and frailty (170);
• In community-dwelling adults aged 65 years and over with 
pre-frailty, a ‘HomeHealth’ trial comprising of 3-6 sessions 
conducted by a trained support worker (delivering skills in 
physical activity, behavioural change techniques, nutrition 
and mood) improved grip strength, capacity-adjusted life-
years and reduced psychological distress compared with 
the control group (n = 51) (171). Other outcomes did not 
improve and health system/carer costs were variable. 
The patient consumer groups also specifically reviewed 
advice on health behaviour improvement for older people with 
frailty, and underlined the importance of a health behaviour 
improvement program that would give them skills to improve 
self-care without needing assistance of family and/or caregivers 
(see Appendix 1.1 for details). The recommendation for home-
based training is aligned with the WHO’s Integrated Care for 
Older People (ICOPE) initiative (172). The task force also 
suggests that home-based training be performed by trained 
health professionals and/or trained volunteers. 
Discussion
This report provides recommendations for the identification 
and management of frailty in older adults developed and 
endorsed by the ICFSR. These recommendations were 
predominantly evidence-based using the GRADE methodology, 
and for sections where research evidence was lacking, best-
practice consensus based recommendations were formed. To 
ensure that older adults with frailty receive the best possible 
quality of care, the next challenge is for the guidelines to be 
incorporated into routine care. 
The ICFSR task force emphasise that these guidelines 
should be used in conjunction with clinical judgement when 
developing care plans for older adults with frailty. Not all older 
adults with frailty will respond to all therapies and treatments, 
particularly those with co-existing conditions or with advanced 
frailty. Each older person will have their own unique needs, and 
principles of personalised medicine should be applied when 
treating/managing frailty (173). Clinicians should be aware 
that in any intervention, benefit should outweigh potential 
patient harm. Whilst this recommendation is common to all 
medical practice, this is particularly important for older adults 
with frailty who unfortunately have an increased likelihood of 
receiving non-beneficial tests and treatments which may expose 
them to unnecessary burden and risk (174). 
Also integral to the management of frailty is shared decision 
making. Shared decision making involves joint consultation 
on decisions between health care providers, patients and 
caregivers to decide upon the best care strategies, and in turn, 
promotes person-centred care. Factors important to older 
persons with frailty need to be incorporated into goals of 
care and treatment decisions, including preferences, values 
and individual priorities (175). The accessibility of resources 
and social support systems, or lack thereof, also needs to be 
accommodated. 
These ICFSR guidelines build on the 2016 Asia-Pacific 
clinical practice guidelines for the management of frailty (33) 
by drawing on evidence from recent systematic reviews which 
have used the GRADE approach. The Asia-Pacific guidelines 
provide regional specific recommendations, including which 
specific cut-off points to use for anthropometric-based frailty 
screening tools, and best-practice interventions for regions with 
low resources and lack of accessibility to geriatrician-based 
care. 
Into the future it will also be important to determine the 
feasibility of using the concept of frailty as a decision making 
tool for treatment goals for older adults with co-existing 
morbidities (176). In addition, from an implementation 
standpoint, these guidelines can be used to generate clinical 
care pathways that are locally adapted.
Guideline Update
Over the next five years, the ICFSR task force will monitor 
the literature for any new advances in technologies or clinical 
treatments. The next update for the ICFSR guidelines on frailty 
is due in 2024, or earlier if breakthrough discoveries are made. 
It is suggested that guidelines for frailty identification and 
management be developed for those research fields with a 
larger evidence base– namely primary care, acute care, 
cardiology, rehabilitation, and oncology. 
Limitations 
These ICFSR guidelines focus on management of the 
individual older person with frailty. They have not been 
designed from a public health perspective, although they have 
the potential for adaptation in order to inform public health 
policies. Important to note is that whilst GRADE guidelines 
were used as the crux of the recommendations, there were 
often sizeable gaps in the evidence-base which limited 
the application of the GRADE methodology. The steering 
committee filled these gaps using consensus-based best practice 
recommendations from the task force, the patient consumer 
groups, and the external evaluation group.   
A major limitation in the formation of the guidelines was 
the lack of quality RCTs upon which to develop the guidelines. 
Although there are many clinical trials on frailty, the majority 
did not measure frailty using validated frailty instruments, and 
in those few studies that did, even fewer re-measured frailty 
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at follow-up. Many trials also had heavy biases, especially 
with regards to patient selection and randomisation errors, 
incomplete datasets due to high attrition rates, and selective 
reporting (56). In addition, most trials were small scale (n < 
200). An additional concern is that systematic reviews of frailty 
have a tendency to combine frailty prevention trials with trials 
for the treatment of frailty/pre-frailty (57, 124-125). Individuals 
with frailty may respond very differently to interventions than 
those without frailty. For instance, older adults with frailty 
have much higher attrition rates in clinical trials than their 
counterparts without frailty. We also highlight the lack of 
person-centred outcome measures used in RCTs on frailty. 
These guidelines have therefore sought the external opinion 
of older adults with frailty via both the patient and healthcare 
consumer groups.
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